Cypress Point Wealth Management LLC Buys New Holdings in Pfizer Inc. $PFE

Key Points

• Cypress Point Wealth Management LLC acquired a new stake in Pfizer Inc., purchasing 11,714 shares valued at approximately $284,000 during the 2nd quarter.
• Several institutional investors made significant adjustments to their positions in Pfizer, with Brighton Jones LLC increasing its stake by 1,282.4% and now owning over 666,000 shares.
• Pfizer reported a quarterly earnings result exceeding estimates, with an EPS of $0.78 on revenue of $14.65 billion, reflecting a 10.3% increase year-over-year.

Cypress Point Wealth Management LLC purchased a new position in Pfizer Inc. (NYSE:PFE - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 11,714 shares of the biopharmaceutical company's stock, valued at approximately $284,000.

Several other large investors have also bought and sold shares of PFE. Vanguard Group Inc. boosted its position in shares of Pfizer by 0.9% during the first quarter. Vanguard Group Inc. now owns 523,165,127 shares of the biopharmaceutical company's stock valued at $13,257,004,000 after buying an additional 4,629,976 shares during the last quarter. Northern Trust Corp lifted its stake in Pfizer by 6.8% during the 1st quarter. Northern Trust Corp now owns 62,325,957 shares of the biopharmaceutical company's stock valued at $1,579,340,000 after acquiring an additional 3,943,397 shares during the period. Amundi boosted its holdings in shares of Pfizer by 43.4% during the 1st quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company's stock valued at $1,265,277,000 after acquiring an additional 15,758,846 shares during the last quarter. Invesco Ltd. grew its stake in shares of Pfizer by 2.8% in the first quarter. Invesco Ltd. now owns 30,296,337 shares of the biopharmaceutical company's stock worth $767,709,000 after acquiring an additional 838,198 shares during the period. Finally, Deutsche Bank AG raised its holdings in shares of Pfizer by 7.0% during the first quarter. Deutsche Bank AG now owns 28,239,197 shares of the biopharmaceutical company's stock valued at $715,581,000 after purchasing an additional 1,846,436 shares during the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Stock Performance

Shares of NYSE PFE traded up $0.11 during trading on Thursday, hitting $24.16. The company had a trading volume of 34,232,417 shares, compared to its average volume of 40,033,748. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $30.43. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The firm has a market capitalization of $137.33 billion, a P/E ratio of 12.85, a price-to-earnings-growth ratio of 0.85 and a beta of 0.55. The stock has a 50 day simple moving average of $24.67 and a 200 day simple moving average of $24.23.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company had revenue of $14.65 billion during the quarter, compared to analyst estimates of $13.43 billion. During the same period in the prior year, the firm posted $0.60 EPS. The firm's quarterly revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 2nd. Investors of record on Friday, July 25th were paid a dividend of $0.43 per share. The ex-dividend date was Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.1%. Pfizer's payout ratio is 91.49%.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. Bank of America raised their target price on shares of Pfizer from $27.00 to $28.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. Morgan Stanley increased their price target on Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a report on Wednesday, August 6th. Berenberg Bank cut their price objective on Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a report on Thursday, May 29th. Citigroup increased their target price on Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a report on Wednesday, August 6th. Finally, Jefferies Financial Group raised their target price on Pfizer from $32.00 to $33.00 and gave the stock a "buy" rating in a research report on Wednesday, May 21st. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $28.12.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.